Gapping up
In reaction to earnings/guidance:
- MTN +4.2%, UEPS +0.6%
Other news:
- LTM +37.8% (LATAM Airlines and Delta confirm airline partnership in Americas; Delta will invest $1.9 bln for 20% stake in LATAM)
- AVXL +6.3% (presented preliminary clinical efficacy data from the PK cohort (Part A) of the U.S. Phase 2 Rett syndrome clinical trial ANAVEX)
- LVS +4.9% (to join S&P 500)
- SGH +4.5% (responds to "inaccurate and misleading statements"; will address on earnings call Oct 3 at 4:30 p.m. ET)
- PSNL +4.4% (awarded new task order from VA's Million Veteran Program; total awarded to-date is now approx. $145 mln)
- NKTR +3.1% (to join S&P MidCap 400)
- PFE +0.8% (New data for bavencio)
- ZUO +0.6% (appoints Adobe VP of strategic and vertical accounts as its Chief Revenue Officer)
- ABBV +0.6% (receives FDA approval of Mavyret)
Analyst comments:
- AGTC +15.3% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- MTCH +4.3% (upgraded to Outperform from In-line at Evercore ISI)
- WU +2.5% (upgraded to Buy from Neutral at Guggenheim)
- IRBT +2% (initiated with a Buy at BofA/Merrill)
- CHD +1.8% (upgraded to Buy from Neutral at BofA/Merrill)
- LYFT +1.2% (initiated with Outperform at Wells Fargo; tgt $60)
- TXN +0.7% (upgraded to Buy from Neutral at BofA/Merrill)